Evogene Ltd.EVGN

時価総額

PER

計算生物学プラットフォームによる医薬・農業・産業向け製品開発の最大手。微生物・低分子・遺伝子向けのAIエンジンによる候補選定と最適化を展開。2024年4月に食品系投資部門と合弁を設立し約40%を出資。米国・欧州・イスラエルで子会社を通じた事業展開。

概要財務

サマリーテーブルに戻る

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Loss	-21	-21	-19	-26	-30	-30	-26	-18
Depreciation	2	2	2	2	1	2	2	2
Amortization of intangible assets	-	-	0	1	1	1	1	1
Share-based compensation	2	2	2	4	3	1	2	2
Remeasurement of Convertible SAFE	-	-	-	-	-	0	0	0
Pre-funded warrants issuance expenses	-	-	-	0	-	-	-	-
Net financing income	-	-	2	-1	1	-3	1	1
Loss (gain) from sale of property, plant and equipment	-	-	-0	-	-0	-	0	-1
Excess of initial fair value of pre-funded warrants over transaction proceeds	-	-	-	-	-	-	-	-3
Amortization of deferred expenses related to issuance of warrants	-	-	-	-	-	-	-	0
Remeasurement of pre-funded warrants and warrants	-	-	-	-	-	-	-	-7
Share of loss of an associate	-	-	-	-	-	-	-	-0
Taxes on income (tax benefit)	0	0	0	0	0	0	-0	0
Adjustments to the profit or loss items	3	4	2	8	4	7	4	1
Increase in trade receivables	0	-0	0	-0	-0	-0	-0	-1
Decrease (increase) in other receivables	0	0	-1	-1	1	1	-1	1
Decrease (increase) in inventories	-	-	-	-	-0	-0	0	-2
Adjustments for deferred tax expense	-	-	-	-	-	-0	0	-
Increase in long term deposits	-0	-	-0	-	-0	-	-	-
Increase (decrease) in trade payables	-0	-0	-0	-0	1	-0	1	-1
Increase (decrease) in employees and payroll accruals	0	-	-0	0	0	-1	1	-1
Increase (decrease) in other payables	0	0	0	-0	0	0	-1	0
Decrease in deferred revenues and other advances	-	-	-	-	0	-0	-0	-1
Changes in asset and liability	-0	-0	-1	-1	2	-1	-0	-3
Interest received	2	1	1	0	0	0	1	1
Interest paid	-	-	0	0	0	0	0	0
Taxes paid	0	0	0	0	0	0	0	0
Net cash used in operating activities	-16	-15	-18	-20	-25	-24	-22	-20
Purchase of property, plant and equipment	1	0	1	1	1	1	1	1
Proceeds from sale of marketable securities	23	64	27	2	4	12	7	-
Purchase of marketable securities	12	32	2	-	23	1	1	-
Proceeds from sale of property, plant and equipment	-	-	-	-	-	-	0	0
Proceeds from short-term bank deposits	-	-	-	-	-	-	-	27
Investment in short-term bank deposits	-	-	-	-	-	-	-	17
Net cash provided by (used in) investing activities	15	17	37	9	-21	13	-5	10
Issuance of a subsidiary's preferred shares to non-controlling interests	-	-	-	-	-	-	10	-
Proceeds from issuance of ordinary shares, pre-funded warrants and warrants	-	-	-	-	-	-	-	6
Proceeds from issue of ordinary shares	-	-	-	19	30	0	8	0
Proceeds from issuance of Convertible SAFE	-	-	-	-	-	10	-	-
Proceeds from exercise of options	1	0	-	0	0	0	-	-
Repayment of lease liabilities	-	-	1	1	1	1	1	1
Proceeds from government grants	0	0	0	0	1	0	1	0
Repayment of government grants	0	0	1	0	0	0	0	0
Net cash provided by financing activities	1	0	9	20	30	9	18	5
Exchange rate differences on cash and cash equivalent balances	0	-0	0	1	1	-2	-0	-0
Decrease in cash and cash equivalents	0	2	29	11	-14	-3	-8	-5
Purchase of property, plant and equipment	0	0	0	0	0	0	0	0
Increase Of Operating Lease Rightofuseassets	-	-	3	-0	1	0	0	2
Exercise of options	-	-	-	0	-	-	-	-
Acquisition of intangible assets	-	-	17	-	-	-	-	-
Exercise of pre-funded warrants	-	-	-	-	4	-	-	2
Investment in affiliated company with corresponding deferred revenues	-	-	-	-	-	-	-	0